These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 32507668)

  • 1. Early stage triple negative breast cancer: Management and future directions.
    Chaudhary LN
    Semin Oncol; 2020 Aug; 47(4):201-208. PubMed ID: 32507668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple-Negative Breast Cancer: Who Should Receive Neoadjuvant Chemotherapy?
    Chaudhary LN; Wilkinson KH; Kong A
    Surg Oncol Clin N Am; 2018 Jan; 27(1):141-153. PubMed ID: 29132557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations.
    Clifton K; Gutierrez-Barrera A; Ma J; Bassett R; Litton J; Kuerer H; Moulder S; Albarracin C; Hortobagyi G; Arun B
    Breast Cancer Res Treat; 2018 Jul; 170(1):101-109. PubMed ID: 29470805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of rates of pathologic complete response and survival.
    Kern P; Kalisch A; von Minckwitz G; Pütter C; Kolberg HC; Pott D; Kurbacher C; Rezai M; Kimmig R
    J Chemother; 2016 Jun; 28(3):210-7. PubMed ID: 26239282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer.
    Stover DG; Winer EP
    Breast; 2015 Nov; 24 Suppl 2():S132-5. PubMed ID: 26255198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Best Foot Forward: Neoadjuvant Systemic Therapy as Standard of Care in Triple-Negative and HER2-Positive Breast Cancer.
    Sharma P; Connolly RM; Roussos Torres ET; Thompson A
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-16. PubMed ID: 32315235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
    von Minckwitz G; Schneeweiss A; Loibl S; Salat C; Denkert C; Rezai M; Blohmer JU; Jackisch C; Paepke S; Gerber B; Zahm DM; Kümmel S; Eidtmann H; Klare P; Huober J; Costa S; Tesch H; Hanusch C; Hilfrich J; Khandan F; Fasching PA; Sinn BV; Engels K; Mehta K; Nekljudova V; Untch M
    Lancet Oncol; 2014 Jun; 15(7):747-56. PubMed ID: 24794243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
    Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant and Neoadjuvant Treatment of Triple-Negative Breast Cancer With Chemotherapy.
    Marra A; Curigliano G
    Cancer J; 2021 Jan-Feb 01; 27(1):41-49. PubMed ID: 33475292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the systemic treatment of triple-negative breast cancer.
    Lebert JM; Lester R; Powell E; Seal M; McCarthy J
    Curr Oncol; 2018 Jun; 25(Suppl 1):S142-S150. PubMed ID: 29910657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy.
    Walsh EM; Shalaby A; O'Loughlin M; Keane N; Webber MJ; Kerin MJ; Keane MM; Glynn SA; Callagy GM
    Breast Cancer Res Treat; 2019 Feb; 174(1):1-13. PubMed ID: 30488345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. De-escalating and escalating systemic therapy in triple negative breast cancer.
    Carey LA
    Breast; 2017 Aug; 34 Suppl 1():S112-S115. PubMed ID: 28690105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.
    Denkert C; von Minckwitz G; Brase JC; Sinn BV; Gade S; Kronenwett R; Pfitzner BM; Salat C; Loi S; Schmitt WD; Schem C; Fisch K; Darb-Esfahani S; Mehta K; Sotiriou C; Wienert S; Klare P; André F; Klauschen F; Blohmer JU; Krappmann K; Schmidt M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Untch M; Loibl S
    J Clin Oncol; 2015 Mar; 33(9):983-91. PubMed ID: 25534375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.
    Lee HJ; Park IA; Song IH; Kim SB; Jung KH; Ahn JH; Ahn SH; Kim HH; Gong G
    PLoS One; 2015; 10(9):e0137885. PubMed ID: 26394326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Platinums in Triple-Negative Breast Cancer.
    Lynce F; Nunes R
    Curr Oncol Rep; 2021 Mar; 23(5):50. PubMed ID: 33754211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of anthracycline and taxane on the expression of programmed cell death ligand-1 and galectin-9 in triple-negative breast cancer.
    Yoon HK; Kim TH; Park S; Jung H; Quan X; Park SJ; Han J; Lee A
    Pathol Res Pract; 2018 Oct; 214(10):1626-1631. PubMed ID: 30139555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A meta-analysis of platinum-based neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy for triple-negative breast cancer.
    Wang D; Feng J; Xu B
    Future Oncol; 2019 Aug; 15(23):2779-2790. PubMed ID: 31293180
    [No Abstract]   [Full Text] [Related]  

  • 20. Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis.
    Li Y; Zhou Y; Mao F; Lin Y; Zhang X; Shen S; Sun Q
    Breast Cancer Res Treat; 2020 Feb; 179(3):533-542. PubMed ID: 31865475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.